ATE347606T1 - Gentherapie für kongestives herzversagen - Google Patents

Gentherapie für kongestives herzversagen

Info

Publication number
ATE347606T1
ATE347606T1 AT97940830T AT97940830T ATE347606T1 AT E347606 T1 ATE347606 T1 AT E347606T1 AT 97940830 T AT97940830 T AT 97940830T AT 97940830 T AT97940830 T AT 97940830T AT E347606 T1 ATE347606 T1 AT E347606T1
Authority
AT
Austria
Prior art keywords
heart failure
congestive heart
gene therapy
present
myocardium
Prior art date
Application number
AT97940830T
Other languages
English (en)
Inventor
H Kirk Hammond
Paul A Insel
Peipei Ping
Steven R Post
Meihua Gao
Original Assignee
Univ California
Collateral Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Collateral Therapeutics filed Critical Univ California
Application granted granted Critical
Publication of ATE347606T1 publication Critical patent/ATE347606T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT97940830T 1996-09-05 1997-09-05 Gentherapie für kongestives herzversagen ATE347606T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70866196A 1996-09-05 1996-09-05
US4893397P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
ATE347606T1 true ATE347606T1 (de) 2006-12-15

Family

ID=26726691

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940830T ATE347606T1 (de) 1996-09-05 1997-09-05 Gentherapie für kongestives herzversagen

Country Status (9)

Country Link
EP (1) EP0934422B1 (de)
JP (1) JP2002514908A (de)
CN (1) CN1234835A (de)
AT (1) ATE347606T1 (de)
AU (1) AU741931B2 (de)
CA (1) CA2262406C (de)
DE (1) DE69737062T2 (de)
EA (1) EA199900261A1 (de)
WO (1) WO1998010085A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
CA2188575A1 (en) 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
DE69733815T2 (de) 1996-02-15 2006-06-08 Biosense Webster, Inc., Diamond Bar Sonde zur exkavation
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US6465237B1 (en) 1997-07-01 2002-10-15 Millennium Pharmaceuticals, Inc. Cloning and characterization of a human adenylyl cyclase
CA2294381A1 (en) * 1997-07-01 1999-01-14 Cor Therapeutics, Inc. Cloning and characterization of a human adenylyl cyclase
US6309370B1 (en) 1998-02-05 2001-10-30 Biosense, Inc. Intracardiac drug delivery
WO1999062940A2 (en) * 1998-05-30 1999-12-09 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US20070265221A1 (en) * 2006-05-09 2007-11-15 Weiss Robert G Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure
CA2705862C (en) * 2007-11-16 2018-03-27 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
AU2008350903B2 (en) 2008-02-19 2015-04-02 Sardocor Corp. Compositions for enhanced uptake of viral vectors in the myocardium

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334521A (en) * 1991-11-18 1994-08-02 American Cyanamid Company Cloning and characterization of a cardiac adenylyl cyclase
US6034071A (en) * 1994-09-16 2000-03-07 Iyengar; Srinivas Ravi V. Mutant activated GS α and adenylyl cyclase 2 for use as therapeutic agents
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
EP0862644A2 (de) * 1995-11-17 1998-09-09 Franz, Wolfgang-M., Dr. Gentherapeutisches nukleinsäurekonstrukt, seine herstellung und verwendung zur behandlung von herzerkrankungen

Also Published As

Publication number Publication date
WO1998010085A2 (en) 1998-03-12
CA2262406A1 (en) 1998-03-12
DE69737062T2 (de) 2007-07-12
JP2002514908A (ja) 2002-05-21
AU4251997A (en) 1998-03-26
EP0934422A2 (de) 1999-08-11
AU741931B2 (en) 2001-12-13
EA199900261A1 (ru) 1999-10-28
EP0934422B1 (de) 2006-12-06
WO1998010085A3 (en) 1998-05-14
CA2262406C (en) 2010-12-07
CN1234835A (zh) 1999-11-10
DE69737062D1 (de) 2007-01-18

Similar Documents

Publication Publication Date Title
ATE347606T1 (de) Gentherapie für kongestives herzversagen
NO962791D0 (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
ATE160178T1 (de) Verfahren und diagnostische kits unter verwendung von säuger-stresspromotoren zur bestimmung der toxizität einer verbindung
AU2789989A (en) Acylated uridine and cytidine and uses thereof
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
EP1180040A4 (de) Methoden zur behandlung von kongestivem herzversagen
DE69929810D1 (de) Verwendung von tetracyclinderivaten zur steigerung der interleukin-10 produktion
EA200000926A1 (ru) Экспрессия генов биосинтеза трегалозы в растениях
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
EP0770089A4 (de) Wachstumsdifferenzierungsfaktor-12
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
EA200100583A1 (ru) Композиции, содержащие лактадгерин или его варианты, и способы их использования
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
WO2001048164A3 (en) Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
DE3767287D1 (de) Potenzierung von prazosin.
FI864597A0 (fi) Kardiotoniska tiazoloner.
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE59904870D1 (de) Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1
ATE317021T1 (de) Antisense modulierung von lfa-3
FI980902A0 (fi) Levosimendaanin stabiileja koostumuksia
ATE79615T1 (de) Cardiotonische phenyloxazolone.
WO1999031136A3 (en) Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
PT925064E (pt) 5-androsteno-3beta,17alfa-diol como um inibidor do crescimento tumoral
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
ATE42201T1 (de) Verwendung von phytosterolglycosiden zur herstellung von arzneimitteln zur behandlung von erhoehtem 5(6)alpha-epoxycholesterolgehalt.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties